Saint Louis, Missouri — According to state and local economic development sources Wugen plans to build out 18,000 square feet of new space in Saint Louis. The company plans to occupy the new space at 4260 Forest Park Avenue in Saint Louis, on or about November 1, 2022. According to the company website Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies. Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.

To learn more about Wugen, visit http://www.wugen.com/

Company Contact:
Dan Kemp, Chief Executive Officer
https://www.linkedin.com/in/kempdaniel/
314-501-1968

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved